Multicentric and diffuse recurrences of meningiomas

References

• Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009;64:56–60; discussion 60.
   PubMed Web of Science ®Google Scholar
• Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 2009;26:69–72.
   PubMed Web of Science ®Google Scholar
• van Alkemade H, de Leau M, Dieleman EM, et al. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol 2012;14:658–66.
   PubMed Web of Science ®Google Scholar
• Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir. 1994;126:53–8.
   PubMed Web of Science ®Google Scholar
• Matsuno A, Fujimaki T, Sasaki T, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 1996;91:504–10.
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas. Cancer 2000;89:1102–10.
   PubMed Web of Science ®Google Scholar
• Maiuri F, De Caro MB, Esposito F, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 2007;82:63–8.
   PubMed Web of Science ®Google Scholar
• Hwang WL, Marciscano AE, Niemierko A, et al. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol 2016;18:863–72.
   PubMed Web of Science ®Google Scholar
• Champeaux C, Dunn L. World Health Organization Grade II meningioma: a 10-year retrospective study for recurrence and prognostic factor assessment. World Neurosurg 2016;89:180–6.
   PubMed Web of Science ®Google Scholar
• Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 1998;29:1420–7.
   PubMed Web of Science ®Google Scholar
• Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg 2011;25:707–13.
   PubMed Web of Science ®Google Scholar
• Oya S, Kawai K, Nakatomi H, Saito N. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. JNS 2012;117:121–8.
   PubMed Web of Science ®Google Scholar
• Sun SQ, Kim AH, Cai C, et al. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 2014;75:347–54. discussion 354-345; quiz 355.
   PubMed Web of Science ®Google Scholar
• Olar A, Wani KM, Sulman EP, et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol 2015;25:266–75.
   PubMed Web of Science ®Google Scholar
• Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. a RANO review. JNS 2015;122:4–23.
   PubMed Web of Science ®Google Scholar
• Sun SQ, Hawasli AH, Huang J, Chicoine MR, Kim AH. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. FOC 2015;38:E3.
   Google Scholar
• Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997;21:1455–65.
   PubMed Web of Science ®Google Scholar
• Ildan F, Erman T, Göçer AI, et al. Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base 2007;17:157–71.
   PubMedGoogle Scholar
• Domingues PH, Sousa P, Otero Á, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol 2014;16:735–47.
   PubMed Web of Science ®Google Scholar
• Magill ST, Dalle Ore CL, Diaz MA, et al. Surgical outcomes after reoperation for recurrent non-skull base meningiomas. J Neurosurg 2019;130:876–883.
   Web of Science ®Google Scholar
• Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J. Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg 1999;90:455–62.
   PubMed Web of Science ®Google Scholar
• McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. JNS 2010;112:925–33.
   PubMed Web of Science ®Google Scholar
• Nawashiro H. Tumor shape and recurrence. J Neurosurg 2000;93:528.
   PubMed Web of Science ®Google Scholar
• Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004;57:1033–7.
   PubMed Web of Science ®Google Scholar
• Wolfsberger S, Doostkam S, Boecher-Schwarz HG, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 2004;27:238–45.
   PubMed Web of Science ®Google Scholar
• Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. JNS 2006;105:163–73.
   PubMed Web of Science ®Google Scholar
• Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22–39.
   PubMed Web of Science ®Google Scholar
• Kleihues PC. Pathology and genetics of tumours of the nervous system. Intl Agency for Research on Cancer; Lyon:IARC Press, 2000.
   Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Borovich B, Doron Y. Recurrence of intracranial meningiomas: the role played by regional multicentricity. J Neurosurg 1986;64:58–63.
   PubMed Web of Science ®Google Scholar
• Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH. World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery 2007;61:1194–8; discussion 1198.
   PubMed Web of Science ®Google Scholar
• Kane AJ, Sughrue ME, Rutkowski MJ, et al. Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 2011;117:1272–8.
   PubMed Web of Science ®Google Scholar
• Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir 2013;155:407–13.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Klironomos G, Taslimi S, et al. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. JNS 2016;125:431–40.
   PubMed Web of Science ®Google Scholar
• Zhou P, Ma W, Yin S, Li Y, Jiang S. Three risk factors for WHO grade II and III meningiomas: A study of 1737 cases from a single center. Neurol India 2013;61:40–4.
   PubMed Web of Science ®Google Scholar
• Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. JNS 2016;125:551–60.
   PubMed Web of Science ®Google Scholar
• Sughrue ME, Kane AJ, Shangari G, et al. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. JNS 2010;113:1029–35.
   PubMed Web of Science ®Google Scholar
• Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB, Rhoton AL. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 1997;39:427–36.
   PubMed Web of Science ®Google Scholar
• Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol 2008;87:43–50.
   PubMed Web of Science ®Google Scholar
• Monleón D, Morales JM, Gonzalez-Segura A, et al. Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res 2010;70:8426–34.
   PubMed Web of Science ®Google Scholar
• Pérez-Magán E, Campos-Martín Y, Mur P, et al. Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 2012;71:882–93.
   PubMed Web of Science ®Google Scholar
• Serna E, Morales JM, Mata M, et al. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PLoS One 2013;8:e67291.
   PubMed Web of Science ®Google Scholar
• Olar A, Wani KM, Wilson CD, et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 2017;133:431–44.
   PubMed Web of Science ®Google Scholar
• Mair R, Morris K, Scott I, Carroll TA. Radiotherapy for atypical meningiomas. JNS 2011;115:811–9.
   PubMed Web of Science ®Google Scholar
• Hardesty DA, Wolf AB, Brachman DG, et al. The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. JNS 2013;119:475–81.
   PubMed Web of Science ®Google Scholar
• Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010;99:393–405.
   PubMed Web of Science ®Google Scholar
• Klinger DR, Flores BC, Lewis JJ, et al. Atypical meningiomas: recurrence, reoperation, and radiotherapy. World Neurosurg 2015;84:839–45.
   PubMed Web of Science ®Google Scholar
• Kano H, Takahashi JA, Katsuki T, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol 2007;84:41–7.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee DH, Kim Rn HJ, Cho YH, Kim JH, Kwon DH. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery. Clin Neurol Neurosurg 2017;153:93–101.
   PubMed Web of Science ®Google Scholar
• Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002;97:341–6.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol 2011;104:765–71.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861–6.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 2011;13:530–5.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012;109:187–93.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 2014;117:93–101.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015;17:116–21.
   PubMed Web of Science ®Google Scholar
• Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus 2018;44:E3.
   PubMed Web of Science ®Google Scholar